PGNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Progyny Inc (PGNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive financial growth and analysts are optimistic with raised price targets, the technical indicators are bearish, and there is no immediate signal from proprietary trading tools. The stock's pre-market price is slightly down, and short-term trends suggest potential further declines. It is better to monitor the stock for a more favorable entry point.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI is neutral at 28.761, and moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 20.231), with resistance levels at R1: 22.958 and R2: 23.801. Short-term stock trends suggest a 60% chance of a -0.63% decline in the next day and a -7.51% decline in the next month.
Analysts have raised price targets and upgraded ratings, citing strong demand, member engagement, and new client wins.
Financials show strong YoY growth in revenue (+9.32%), net income (+33.04%), and EPS (+36.36%).
The company is building on its industry-leading position in fertility and family-building solutions.
Technical indicators are bearish, suggesting potential short-term price declines.
No recent news or significant trading trends from hedge funds or insiders.
Congress trading data is absent, and proprietary trading signals (AI Stock Picker and SwingMax) do not indicate a buy opportunity.
In Q3 2025, Progyny reported revenue of $313.35M (+9.32% YoY), net income of $13.86M (+33.04% YoY), EPS of $0.15 (+36.36% YoY), and gross margin of 23.24% (+12.43% YoY). These figures indicate strong financial growth and operational efficiency.
Analysts are optimistic about Progyny, with multiple firms raising price targets and upgrading ratings. BTIG raised the price target to $35, citing strong demand and favorable member engagement. Citizens upgraded the stock to Outperform with a $30 price target, highlighting retention rates and new solutions. Truist upgraded the stock to Buy with a $34 price target, citing resilient demand and improved visibility. However, KeyBanc noted potential valuation impacts due to competition and regulatory concerns.
